H35.382
Toxic maculopathy, left eye
Clinical Classification Guidelines
Medical Intelligence & Overview
Toxic maculopathy refers to damage to the macula—the central part of the retina responsible for sharp, detailed vision—caused by toxic substances. When this damage affects the left eye specifically, it is classified under ICD-10 code H35.382. This condition can result from exposure to certain chemicals, drugs, or other harmful agents, leading to visual impairment if not properly managed. The following overview emphasizes the nature of this condition, its causes, symptoms, diagnostic methods, and potential treatments, aiming to provide a clear understanding for patients and caregivers.
Causes & Symptoms
Clinical Causes: Exposure to certain medications such as chloroquine, hydroxychloroquine, or thioridazine Contact with industrial chemicals or toxins that can reach ocular tissues Prolonged use of drugs known for retinal toxicity Accidental or intentional exposure to harmful substances causing toxicity in the eye Metabolic or systemic conditions that result in the accumulation of toxic substances in ocular tissues
Key Symptoms: Gradual or sudden loss of central vision in the left eye Blurred or distorted vision affecting daily activities Difficulty recognizing faces or reading fine print Possible presence of a central scotoma (a dark or blank spot in the visual field) Photophobia, or sensitivity to light Color vision disturbances, particularly in the central visual field
Diagnostic & Treatment
Diagnosis Path: Diagnosing toxic maculopathy involves a combination of clinical evaluation and specialized tests: - Comprehensive eye examination to assess visual acuity and retinal health - Optical coherence tomography (OCT) to visualize retinal layers and detect structural abnormalities in the macula - Fluorescein angiography to evaluate blood flow and identify any retinal vascular damage - Review of medication history and exposure to potential toxins - Additional blood tests if systemic toxicity or metabolic conditions are suspected Early detection is crucial to prevent permanent damage and visual loss.
Treatment Protocols: Managing toxic maculopathy primarily focuses on halting exposure to the causative agent and preventing further damage: - Immediate discontinuation of the suspected toxic medication or chemical - Regular monitoring of visual function and retinal health - Use of antioxidants or other supportive therapies, as recommended by healthcare providers - Optical aids or low vision devices to assist with daily activities if vision impairment persists - Potential consultation with a retinal specialist for advanced interventions While some damage to the macula may be irreversible, early intervention can stabilize visual decline and preserve remaining vision. Follow-up care is essential for ongoing assessment and management.
Clinical Advice & FAQs
Billing Guidance
Is H35.382 a billable ICD-10 code?
Yes, H35.382 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report H35.382?
Clinical documentation must specify the nature of Toxic maculopathy, left eye and any associated comorbidities for accurate reporting.
Cite this Clinical Reference